From Military To Medicine, Owlstone Medical Targets Lung Cancer With Its Breath Analysis Tech
Owlstone Medical is on a mission to “save 100,000 lives and £1.5bn in health-care costs by 2020” by applying a gas sensor technology, originally developed for military defense purposes, for early stage detection of lung cancer.
You may also be interested in...
A micropump technology from UK company TTP Ventus is powering a new wearable sleep apnea product developed by San Diego-based company Sommetrics. The device is currently approved for marketing to people with all degrees of sleep apnea in Canada. TTP's pump know-how is also being applied to IVD technologies, including a breathalyzer and microfluidic-based diagnostic devices.
Early diagnosis of lung cancer continues to be a major clinical challenge and the opportunity for products that can successfully detect the disease early enough to boost survival rate is huge. This article looks into the market potential and highlights companies developing technologies that they believe can finally turn this deadliest of cancers on its head.
Quanta Dialysis has signed an agreement with B. Braun to provide support services to Quanta’s patients in the UK. The hemodialysis firm launched its compact hemodialysis device SC+ on the market at the beginning of the year.